Spoken Alpha
LENZ Therapeutics, Inc.
LENZ Therapeutics designs and commercializes VIZZ, a once-daily prescription eye drop containing aceclidine for treating presbyopia (age-related near vision loss). The company sells VIZZ directly to U.S. consumers through eye care professionals and retail pharmacies, and is establishing international licensing partnerships for global distribution.
LENZ Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $142.0M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
8 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LENZ.
$ curl https://api.spokenalpha.com/v1/companies/LENZFAQ
Spoken Alpha indexes LENZ's earnings call transcripts at https://spokenalpha.com/companies/LENZ. Each call links to attributed speakers and parsed analyst Q&A. LENZ Therapeutics, Inc.'s own investor relations page is at https://ir.lenz-tx.com/.
LENZ Therapeutics, Inc. (LENZ) held its most recent earnings call on 2026-05-11, covering fiscal Q1 2026.
LENZ Therapeutics, Inc. (LENZ) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-1.01 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-10 | $-1.02 | $-1.21 | +15.7% | $5.5M | — | — | EODHD |
| Q4 FY2025 | 2026-03-30 | $-1.32 | $-1.07 | -23.3% | $1.9M | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-0.59 | $-0.67 | +11.9% | $12.5M | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $-0.53 | $-0.54 | +1.8% | $5.0M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.53 | $-0.32 | -65.6% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-18 | $-0.46 | $-0.42 | -9.5% | $66.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.38 | $-0.43 | +11.6% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.40 | $-0.67 | +40.3% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-3.53 | $-0.82 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-02-26 | $-0.40 | $-0.13 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-0.24 | $-0.24 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-09-10 | $-6.79 | $-0.97 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-3.01 | $-0.40 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-19 | $-3.08 | $-0.49 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-3.15 | $-0.44 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-3.36 | $-0.49 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-3.36 | $-0.39 | -100.0% | — | — | — | EODHD |
| Q4 FY2021 | 2022-03-20 | $-2.45 | $-0.30 | -100.0% | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-0.06 | $-0.28 | +78.3% | — | — | — | EODHD |
Source: EODHD. LENZ reported actuals as published; sparse fields render as —.